173 related articles for article (PubMed ID: 35323332)
1. Sequential Use of Carfilzomib and Pomalidomide in Relapsed Multiple Myeloma: A Report from the Canadian Myeloma Research Group (CMRG) Database.
McCurdy A; Venner CP; Masih-Khan E; Louzada M; LeBlanc R; Sebag M; Song K; Jimenez-Zepeda VH; Kotb R; Kardjadj M; Mian H; White D; Stakiw J; Aslam M; Reiman A; Gul E; Reece D
Curr Oncol; 2022 Mar; 29(3):1575-1582. PubMed ID: 35323332
[TBL] [Abstract][Full Text] [Related]
2. Clinical efficacy of daratumumab, pomalidomide, and dexamethasone in patients with relapsed or refractory myeloma: Utility of re-treatment with daratumumab among refractory patients.
Nooka AK; Joseph NS; Kaufman JL; Heffner LT; Gupta VA; Gleason C; Boise LH; Lonial S
Cancer; 2019 Sep; 125(17):2991-3000. PubMed ID: 31090928
[TBL] [Abstract][Full Text] [Related]
3. Carfilzomib/pomalidomide single-agent or in combination with other agents for the management of relapsed/refractory multiple myeloma: a meta-analysis of 37 trials.
Zou Y; Ma X; Yu H; Hu C; Fan L; Ran X
Oncotarget; 2017 Jun; 8(24):39805-39817. PubMed ID: 27458170
[TBL] [Abstract][Full Text] [Related]
4. Cost-effectiveness of Pomalidomide, Carfilzomib, and Daratumumab for the Treatment of Patients with Heavily Pretreated Relapsed-refractory Multiple Myeloma in the United States.
Pelligra CG; Parikh K; Guo S; Chandler C; Mouro J; Abouzaid S; Ailawadhi S
Clin Ther; 2017 Oct; 39(10):1986-2005.e5. PubMed ID: 28967482
[TBL] [Abstract][Full Text] [Related]
5. Real-Life Experience with Pomalidomide plus Low-Dose Dexamethasone in Patients with Relapsed and Refractory Multiple Myeloma: A Retrospective and Prospective Study.
Del Giudice ML; Gozzetti A; Antonioli E; Orciuolo E; Ghio F; Ciofini S; Candi V; Fontanelli G; Attucci I; Formica G; Bocchia M; Galimberti S; Petrini M; Buda G
Medicina (Kaunas); 2021 Aug; 57(9):. PubMed ID: 34577823
[No Abstract] [Full Text] [Related]
6. Clinical outcomes of pomalidomide-based and daratumumab-based therapies in patients with relapsed/refractory multiple myeloma: A real-world cohort study in China.
Han X; Jiang X; He J; Zheng G; Xiong Y; Wen Y; Yang Y; He D; Chen Q; Zhao Y; Li Y; Wu W; Cai Z
Cancer Med; 2024 May; 13(9):e7232. PubMed ID: 38698679
[TBL] [Abstract][Full Text] [Related]
7. Pomalidomide and Low-Dose Dexamethasone Improves Health-Related Quality of Life and Prolongs Time to Worsening in Relapsed/Refractory Patients With Multiple Myeloma Enrolled in the MM-003 Randomized Phase III Trial.
Weisel K; Dimopoulos M; Song KW; Moreau P; Palumbo A; Belch A; Schey S; Sonneveld P; Sternas L; Yu X; Amatya R; Gibson CJ; Zaki M; Jacques C; San Miguel J
Clin Lymphoma Myeloma Leuk; 2015 Sep; 15(9):519-30. PubMed ID: 26149712
[TBL] [Abstract][Full Text] [Related]
8. Real-World Treatment Patterns, Time to Next Treatment, and Economic Outcomes in Relapsed or Refractory Multiple Myeloma Patients Treated with Pomalidomide or Carfilzomib.
Chen CC; Parikh K; Abouzaid S; Purnomo L; McGuiness CB; Hussein M; Wade RL
J Manag Care Spec Pharm; 2017 Feb; 23(2):236-246. PubMed ID: 28125372
[TBL] [Abstract][Full Text] [Related]
9. Daratumumab plus pomalidomide and dexamethasone in relapsed and/or refractory multiple myeloma.
Chari A; Suvannasankha A; Fay JW; Arnulf B; Kaufman JL; Ifthikharuddin JJ; Weiss BM; Krishnan A; Lentzsch S; Comenzo R; Wang J; Nottage K; Chiu C; Khokhar NZ; Ahmadi T; Lonial S
Blood; 2017 Aug; 130(8):974-981. PubMed ID: 28637662
[TBL] [Abstract][Full Text] [Related]
10. Healthcare utilization and costs among relapsed or refractory multiple myeloma patients on carfilzomib or pomalidomide as monotherapy or in combination with dexamethasone.
Hagiwara M; Panjabi S; Sharma A; Delea TE
J Med Econ; 2019 Aug; 22(8):818-829. PubMed ID: 31046501
[No Abstract] [Full Text] [Related]
11. Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003): a randomised, open-label, phase 3 trial.
Miguel JS; Weisel K; Moreau P; Lacy M; Song K; Delforge M; Karlin L; Goldschmidt H; Banos A; Oriol A; Alegre A; Chen C; Cavo M; Garderet L; Ivanova V; Martinez-Lopez J; Belch A; Palumbo A; Schey S; Sonneveld P; Yu X; Sternas L; Jacques C; Zaki M; Dimopoulos M
Lancet Oncol; 2013 Oct; 14(11):1055-1066. PubMed ID: 24007748
[TBL] [Abstract][Full Text] [Related]
12. Daratumumab plus pomalidomide and dexamethasone versus pomalidomide and dexamethasone alone in previously treated multiple myeloma (APOLLO): an open-label, randomised, phase 3 trial.
Dimopoulos MA; Terpos E; Boccadoro M; Delimpasi S; Beksac M; Katodritou E; Moreau P; Baldini L; Symeonidis A; Bila J; Oriol A; Mateos MV; Einsele H; Orfanidis I; Ahmadi T; Ukropec J; Kampfenkel T; Schecter JM; Qiu Y; Amin H; Vermeulen J; Carson R; Sonneveld P;
Lancet Oncol; 2021 Jun; 22(6):801-812. PubMed ID: 34087126
[TBL] [Abstract][Full Text] [Related]
13. The European medicines agency review of pomalidomide in combination with low-dose dexamethasone for the treatment of adult patients with multiple myeloma: summary of the scientific assessment of the committee for medicinal products for human use.
Hanaizi Z; Flores B; Hemmings R; Camarero J; Sancho-Lopez A; Salmonson T; Gisselbrecht C; Laane E; Pignatti F
Oncologist; 2015 Mar; 20(3):329-34. PubMed ID: 25673103
[TBL] [Abstract][Full Text] [Related]
14. Pomalidomide, bortezomib, and dexamethasone for patients with relapsed or refractory multiple myeloma previously treated with lenalidomide (OPTIMISMM): a randomised, open-label, phase 3 trial.
Richardson PG; Oriol A; Beksac M; Liberati AM; Galli M; Schjesvold F; Lindsay J; Weisel K; White D; Facon T; San Miguel J; Sunami K; O'Gorman P; Sonneveld P; Robak P; Semochkin S; Schey S; Yu X; Doerr T; Bensmaine A; Biyukov T; Peluso T; Zaki M; Anderson K; Dimopoulos M;
Lancet Oncol; 2019 Jun; 20(6):781-794. PubMed ID: 31097405
[TBL] [Abstract][Full Text] [Related]
15. Outcome of treatment with carfilzomib before and after treatment with daratumumab in relapsed or refractory multiple myeloma patients.
Højholt KL; Gregersen H; Szabo AG; Klausen TW; Levring MB; Preiss B; Helleberg C; Breinholt MF; Hermansen E; Rahbek Gjerdrum LM; Bønløkke ST; Nielsen K; Kjeldsen E; Iversen KF; Teodorescu EM; Kurt E; Strandholdt C; Andersen MK; Vangsted AJ
Hematol Oncol; 2021 Oct; 39(4):521-528. PubMed ID: 34342035
[TBL] [Abstract][Full Text] [Related]
16. Indatuximab ravtansine plus dexamethasone with lenalidomide or pomalidomide in relapsed or refractory multiple myeloma: a multicentre, phase 1/2a study.
Kelly KR; Ailawadhi S; Siegel DS; Heffner LT; Somlo G; Jagannath S; Zimmerman TM; Munshi NC; Madan S; Chanan-Khan A; Lonial S; Chandwani S; Minasyan A; Ruehle M; Barmaki-Rad F; Abdolzade-Bavil A; Rharbaoui F; Herrmann-Keiner E; Haeder T; Wartenberg-Demand A; Anderson KC
Lancet Haematol; 2021 Nov; 8(11):e794-e807. PubMed ID: 34529955
[TBL] [Abstract][Full Text] [Related]
17. Multiagent therapy with pomalidomide, bortezomib, doxorubicin, dexamethasone, and daratumumab ("Pom-PAD-Dara") in relapsed/refractory multiple myeloma.
Zhou X; Steinhardt MJ; Grathwohl D; Meckel K; Nickel K; Leicht HB; Krummenast F; Einsele H; Rasche L; Kortüm KM
Cancer Med; 2020 Aug; 9(16):5819-5826. PubMed ID: 32608149
[TBL] [Abstract][Full Text] [Related]
18. Carfilzomib, dexamethasone, and daratumumab versus carfilzomib and dexamethasone for patients with relapsed or refractory multiple myeloma (CANDOR): results from a randomised, multicentre, open-label, phase 3 study.
Dimopoulos M; Quach H; Mateos MV; Landgren O; Leleu X; Siegel D; Weisel K; Yang H; Klippel Z; Zahlten-Kumeli A; Usmani SZ
Lancet; 2020 Jul; 396(10245):186-197. PubMed ID: 32682484
[TBL] [Abstract][Full Text] [Related]
19. Outcome of carfilzomib/pomalidomide-based regimens after daratumumab-based treatment in relapsed multiple myeloma: A Canadian Myeloma Research Group Database analysis.
LeBlanc R; Mian H; Reece D; Su J; Masih-Khan E; Chu M; Jimenez-Zepeda V; Sebag M; Song K; Louzada M; Kotb R; Visram A; White D; Stakiw J; Reiman A; Aslam M; Bergstrom D; Kaedbey R; Gul E; Venner C
Eur J Haematol; 2023 Nov; 111(5):815-823. PubMed ID: 37574220
[TBL] [Abstract][Full Text] [Related]
20. Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): a randomised, multicentre, open-label, phase 3 study.
Attal M; Richardson PG; Rajkumar SV; San-Miguel J; Beksac M; Spicka I; Leleu X; Schjesvold F; Moreau P; Dimopoulos MA; Huang JS; Minarik J; Cavo M; Prince HM; Macé S; Corzo KP; Campana F; Le-Guennec S; Dubin F; Anderson KC;
Lancet; 2019 Dec; 394(10214):2096-2107. PubMed ID: 31735560
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
